Skip to content
AnalystLens

ECOLAB INC. Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed October 31, 2024
Period End
September 30, 2024
Security
ECL
One revenue dollarkept$0.18
In the record · 2016–202610-K1110-Q328-K144

ECL filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 144 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’19Feb ’19
  2. Restructuring8-K · Feb ’21Feb ’21
  3. Restructuring8-K · Nov ’22Nov ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.

Ecolab Inc. (ECL) reported a strong third quarter for fiscal year 2024, demonstrating robust sales growth and significant improvements in profitability.

Net sales increased by 1% to $3,998.5 milliona, with organic sales growing by 4%, indicating healthy underlying business momentum across its key segments. The company experienced notable margin expansion, with reported gross margin improving to 43.4% from 41.1% in the prior year period, driven by effective value pricing and lower delivered product costs. Profitability saw a substantial uplift, with reported operating income surging by 85% year-over-year to $1,044.8 million.

Net income attributable to Ecolab more than doubled to $736.5 millionb, and diluted EPS rose by 83% to $2.58. These gains were bolstered by the significant gain on the sale of the global surgical solutions business, but even on an adjusted basis, the company showed solid growth, with adjusted diluted EPS increasing by 19%. Ecolab continues to execute on its strategic initiatives, including the 'One Ecolab' program aimed at driving growth and margin expansion, and maintains a strong liquidity position with substantial cash reserves and available credit facilities.

Key Highlights

  1. Net sales increased by 1% to $3,998.5 million in Q3 2024, with organic sales up 4%.
  2. Reported operating income increased by 85% to $1,044.8 million, and net income attributable to Ecolab rose 82% to $736.5 million.
  3. Diluted EPS saw a significant increase of 83% to $2.58.
  4. Gross margin improved to 43.4% from 41.1% in Q3 2023, reflecting strong pricing and lower costs.
  5. The company recognized a significant gain of $365.3 million from the sale of its global surgical solutions business.
  6. Ecolab is advancing its 'One Ecolab' initiative to enhance growth and margin expansion, with ongoing restructuring plans.
  7. The company maintained a strong liquidity position, with $1,261.1 million in cash and cash equivalents.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2024, Ecolab Inc. kept $0.18.

  1. Revenue$4.00B100.0%
  2. Cost of revenue−$2.26B56.6%
  3. Gross profit$1.74B43.4%
  4. Operating costs−$692.2M17.3%
  5. Operating income$1.04B26.1%
  6. Interest, other & tax−$308.3M7.7%
  7. Net income$736.5M18.4%
Computed from 10-QQ3 FY2024filed October 31, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$4.00B$3.96B+1.0%
Cost of Revenue$2.26B$2.33B−3.0%
Gross Profit$1.74B$1.63B+6.7%
SG&A Expenses$1.02B$1.02B0.0%
Operating Income$1.04B$566.00M+84.6%
Interest Expense$86.40M$91.30M−5.4%
Net Income$736.50M$404.00M+82.3%
EPS (Basic)$2.60$1.42+83.1%
EPS (Diluted)$2.58$1.41+83.0%
Shares Outstanding (Basic)283.60M285.10M−0.5%
Shares Outstanding (Diluted)286.00M286.90M−0.3%

Frequently Asked Questions

  1. What were the main drivers of Ecolab's revenue growth in Q3 2024?

    Ecolab's revenue growth in Q3 2024 was driven by a 4% increase in organic sales. This growth was observed across multiple segments, with notable contributions from Global Institutional & Specialty (up 7% organically) and Global Pest Elimination (up 8% organically). Strong value pricing and increased volumes were key factors contributing to this expansion.

  2. How did the sale of the global surgical solutions business impact Ecolab's financial results?

    The sale of the global surgical solutions business, which closed on August 1, 2024, resulted in a pre-tax gain of $365.3 million ($264.2 million after tax), or $0.92 per diluted share, recognized in the third quarter of 2024. This significantly boosted the company's net income and earnings per share for the period.

  3. What is the 'One Ecolab' initiative and what are its expected impacts?

    The 'One Ecolab' initiative, announced in July 2024, is designed to enhance the company's growth and margin expansion. As part of this, Ecolab commenced a restructuring plan to leverage digital technologies and consolidate functional work into global centers of excellence. The company anticipates total restructuring costs of $175 million and special charges of $50 million by the end of 2027. This initiative has already delivered $8 million in cumulative cost savings and is expected to generate annualized cost savings of $225 million by 2027.

  4. How is Ecolab managing its debt and what is its liquidity position?

    Ecolab continues to manage its debt effectively, with total debt decreasing to $7.6 billion as of September 30, 2024, from $8.2 billion at the end of 2023. The company's net debt to EBITDA ratio improved to 1.7 from 2.4. Ecolab maintains a strong liquidity position with $1,261.1 million in cash and cash equivalents and an undrawn $2.0 billion revolving credit facility, ensuring ample resources to fund operations, investments, and capital returns.